Report: Finosa shares ¡V a good time to buy?

Introduction
Finosa has a new drug to treat narrowed arteries, called Vipax. At a recent presentation, Mr. Gerard Haberer said that Vipax is very important product and expected to find a very big market for this product.

Findings
1. The Bergamot cosmetics group owned 53% of Finosa¡¦s shares. Four weeks ago Bergamot announced that they want to sell some of these shares. As a result, Fionsa¡¦s share price has climbed from 70 euros to 84 euros.
2. The pharmaceuticals industry has been going through a period of consolidation, with a lot of mergers and acquisitions.
3. Mr. Phillipe Cottet, a pharmaceuticals analyst in Paris, wrote Finosa are making very optimistic sales forecasts, because the price of Finosa shares already includes the profit potential of their new products.
4. Finosa is the world¡¦s 12th largest pharmaceuticals company in terms of sales.
5. The medical journal ¡¥The Doctor¡¦ said ¡¥The benefits of using Vipax are exaggerated. The high cost Vipax in comparison with existing treatments such as aspirin will restrict its sales.¡¦

Analysis
The Paris stock exchange is full of rumours that another French drugs group, Labsynth, is interested in forming some sort of merger with Finosa. But, Labsynth have denied these rumours.

Recommendations and Conclusion
Consequently, I highly recommend stock shareholders invest in Finosa Pharmaceuticals Company, as they got a good reputation and invest a new drug, Vipax, a very important product.